UP!

GLYC $1.86

GLYC target price
1.85
0
0

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-10-31 Future report Set alerts
Q2 2022 2022-08-03 -0.25 -0.25
Q1 2022 2022-04-28 -0.28 -0.28
Q4 2021 2022-03-03 -0.33 -0.33
Q3 2021 2021-11-02 -0.34 -0.34
Q2 2021 2021-08-05 -0.28 -0.28
Q1 2021 2021-05-03 -0.28 -0.28
Q4 2020 2021-03-02 -0.32 -0.32
Q2 2020 2020-07-31 -0.32 0.00
Q1 2020 2020-05-01 -0.18 -0.18

Ratings

2016-05-04 Reiterated Rating Canaccord Genuity Buy $12.00
2016-03-01 Reiterated Rating Canaccord Genuity Buy $12.00
2016-03-01 Lower Price Target Jefferies Group Buy $14.00 to $11.00
2015-12-08 Reiterated Rating Canaccord Genuity Buy $12.00
2015-11-12 Reiterated Rating Canaccord Genuity Buy $12.00
2015-08-10 Reiterated Rating Canaccord Genuity Buy $12.00
2015-06-05 Reiterated Rating Jefferies Group Buy $14.00
2015-05-06 Reiterated Rating Jefferies Group Buy to Buy $18.00 to $14.00
2015-04-07 Set Price Target Canaccord Genuity Buy $12.00
2015-03-17 Boost Price Target Stifel Nicolaus Buy $13.00 to $14.00
2015-01-25 Reiterated Rating Canaccord Genuity Buy $12.00
2014-04-15 Boost Price Target Stifel Nicolaus Buy $14.00 to $16.00
2014-04-01 Boost Price Target Jefferies Group $13.00 to $20.00
2014-02-04 Initiated Coverage Barclays Overweight $15.00
2014-02-04 Initiated Coverage Canaccord Genuity Buy
2014-02-04 Initiated Coverage Stifel Nicolaus Buy $14.00
2014-02-04 Initiated Coverage Jefferies Group Buy $13.00
2016-05-04 Reiterated Rating Canaccord Genuity Buy $12.00
2016-03-01 Reiterated Rating Canaccord Genuity Buy $12.00
2016-03-01 Lower Price Target Jefferies Group Buy $14.00 to $11.00
2015-12-08 Reiterated Rating Canaccord Genuity Buy $12.00
2015-11-12 Reiterated Rating Canaccord Genuity Buy $12.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
BARRETT M JAMES 23.77%  (4491203) ADNC / ARDX / CLVS / CRCM / CVT / DATA / ECHO / EPZM / FOLD / GLYC / HIVE / HPTX / INWK / LOXO / ROKA / SNSS / SUPN / SURF / SYBX / TRGT / TSRO / VTAE / WIFI / XOOM / ZSAN /
SANDELL SCOTT D 23.77%  (4490751) ABIO / ADNC / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / DATA / ECHO / EPZM / FIO / GLYC / HIVE / HPTX / INWK / LOXO / ONTY / ROKA / SNSS / SUPN / SURF / SYBX / TRGT / TSRO / VTAE / WDAY / WIFI / XOOM /
BARRIS PETER J 23.77%  (4490751) ABIO / ADNC / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / DATA / ECHO / EPZM / GLYC / GRPN / HIVE / HPTX / INWK / LOXO / ONTY / ROKA / SNSS / SUPN / SURF / SYBX / TRGT / TSRO / VTAE / WIFI / XOOM / ZHNE /
NEW ENTERPRISE ASSOCIATES 10 L P 23.77%  (4490751) GLUU / GLYC / VTAE / WIFI /
NEW ENTERPRISE ASSOCIATES 13 LP 21.67%  (4093377) CLVS / CRCM / CVT / EPZM / GLYC / HIVE / ROKA / TSRO /
HENOS MICHAEL A 2.48%  (469454) GLYC /
Gust William M. 2.17%  (409947) GLYC /
Thackray Helen M. VP Clinical Development, CMO 0.79%  (148615) GLYC /
King Rachel K. President, CEO 0.58%  (108706) GLYC /
Magnani John L. VP of Research, CSO 0.48%  (90374) GLYC /
Hahn Brian M. CFO 0.07%  (14085) GLYC /
TOP FRANKLIN H JR 0.07%  (12294) GLYC /
Goldberg Mark Alan 0.06%  (11497) BOLD / GEVA / GLYC / IDRA / IMGN /
JUNIUS DANIEL M 0.04%  (8000) GLYC / IDXX / IMGN / VTAE /
Baldwin John J. 0.01%  (1210) GLYC /